Eli Lilly and Company (LLY) — RQD Stock Rating Cockpit

$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot

Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.

ROARABLE B • BUY Cap $1.33T
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Cash (19)Whales (14)SEC (12)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
$1824 Bull$1690 Base$1473 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
RSI-14 MOMENTUMOVERBOUGHT (>70)
77.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
9.29>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE88% OF RANGE
L: $810$1,373.70H: $1,450
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (84% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on LLY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (95)

32.4% ROIC with 83.6% gross margin and 2.30% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 9.29 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (68)

Put/Call 1.48x with 27/40 institutional & insider flow.

Bull Case: Why Buyers Like LLY
  • ✓Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Tier-1 Profitability and Compounding Free Cash Flow Conversion
Bear Case: What Could Go Wrong
  • !Priced at 48x earnings—high expectations leave less room for a lukewarm quarter.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Senior Cash-Flow & Income Strategist

Cash-Fortress Compounders: Collecting Safe Yield & Upside in LLY & Top A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector rival
  • ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
  • ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
$1,491.6$1,317.9$1,144.1$970.3$796.6RES $1,364.7$1,417.52026-05-012026-06-122026-07-312026-09-112026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)
-0.53% YoY Shares

SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.

Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth

vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim

Trigger: $1452.98 • Invalidation: $1349.50

🦋 Documented & Second-Order Butterfly Connections Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.

LLY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LLY stock right now?

Eli Lilly and Company (LLY) currently earns a Roarable Rating of B (Buy — BUY) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support.

What is LLY's 12-month price target and RQD AI Jury consensus?

LLY's 12-month base price target is $1689.78 (range $1472.9 to $1824.45), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.